{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "4ca20d01",
   "metadata": {},
   "source": [
    "/usr/local/lib/python3.11/dist-packages/huggingface_hub/utils/_auth.py:94: UserWarning: \n",
    "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
    "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
    "You will be able to reuse this secret in all of your notebooks.\n",
    "Please note that authentication is recommended but still optional to access public models or datasets.\n",
    "  warnings.warn(\n",
    "tokenizer_config.json:â€‡100%\n",
    "â€‡366/366â€‡[00:00<00:00,â€‡43.8kB/s]\n",
    "vocab.txt:â€‡100%\n",
    "â€‡232k/232kâ€‡[00:00<00:00,â€‡16.9MB/s]\n",
    "tokenizer.json:â€‡100%\n",
    "â€‡711k/711kâ€‡[00:00<00:00,â€‡3.14MB/s]\n",
    "special_tokens_map.json:â€‡100%\n",
    "â€‡125/125â€‡[00:00<00:00,â€‡15.9kB/s]\n",
    "config.json:â€‡100%\n",
    "â€‡779/779â€‡[00:00<00:00,â€‡102kB/s]\n",
    "model.safetensors:â€‡100%\n",
    "â€‡1.34G/1.34Gâ€‡[00:03<00:00,â€‡410MB/s]\n",
    "ðŸ”„ No cached vectors found. Computing now...\n",
    "\n",
    "ðŸŸ¦ QUESTION 1: My patient is interested in lifestyle interventions for a major depressive episode of mild severity that does not have a seasonal pattern. What is the first line recommendation?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a major depressive episode of mild severity without a seasonal pattern, the first-line lifestyle intervention recommended is supervised exercise. The CANMAT guidelines support the use of low to moderate intensity exercise, performed for 30 to 40 minutes at a time, 3 to 4 times a week, for a minimum of 9 weeks as a first-line monotherapy for mild depression. This recommendation is based on substantial evidence showing that exercise is effective in reducing depressive symptoms and provides additional health benefits.\n",
    "\n",
    "ðŸŸ¦ QUESTION 2: My patient has a major depressive episode with seasonal pattern and would like to try lifestyle interventions first. Other than exercise, what is a first line option for them?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient experiencing a major depressive episode with a seasonal pattern, light therapy is recommended as a first-line lifestyle intervention. According to the CANMAT guidelines, light therapy involves timed exposure to 10,000 lux fluorescent white light for 30 minutes daily in the morning shortly after awakening. This intervention is supported by several consistent meta-analyses and is considered effective for seasonal (winter) depression.\n",
    "\n",
    "ðŸŸ¦ QUESTION 3: My patient has a major depressive episode with somatic symptoms of pain, what would be the first choice medication for them?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient experiencing a major depressive episode with somatic symptoms of pain, the CANMAT guidelines suggest that SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), such as duloxetine, may offer more benefits compared to SSRIs (Selective Serotonin Reuptake Inhibitors) for comorbid pain conditions (Section: How do DSM-5-TR Specifiers and Symptom Dimensions Influence Medication Selection?). This recommendation is based on evidence indicating that SNRIs can be more effective in addressing both depressive symptoms and associated pain. Therefore, an SNRI like duloxetine would be a preferred first-choice medication for this patient.\n",
    "\n",
    "ðŸŸ¦ QUESTION 4: My patient has a major depressive episode with somatic symptoms of fatigue, what would be the first choice medication for them?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient experiencing a major depressive episode with somatic symptoms such as fatigue, the CANMAT guidelines suggest that SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) may be a preferable choice over SSRIs, as they may better address symptoms of energy, fatigue, and motivation (Section: Q.3.g. How do DSM-5-TR Specifiers and Symptom Dimensions Influence Medication Selection?). This recommendation is based on evidence indicating that SNRIs have superior efficacy for these specific symptoms compared to SSRIs.\n",
    "\n",
    "ðŸŸ¦ QUESTION 5: My patient with a major depressive episode of mild severity would like to try psychotherapy. What are the first-line options?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient with a major depressive episode of mild severity who prefers psychotherapy, the CANMAT guidelines recommend evidence-based psychotherapy as a first-line treatment. Specifically, Cognitive-behavioral therapy (CBT), interpersonal therapy (IPT), and behavioral activation (BA) are supported as first-line psychological treatments for the acute management of major depressive disorder. These therapies have robust evidence for efficacy and can be delivered in various formats, including individual, group, and digital methods.\n",
    "\n",
    "ðŸŸ¦ QUESTION 6: My patient with a major depressive episode of mild severity is interested in complementary and alternative medicine options. What would be the most appropriate option to present?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient with a major depressive episode of mild severity interested in complementary and alternative medicine (CAM) options, St. John's wort is recommended as a first-line treatment due to its Level 1 evidence for efficacy in mild depression. However, caution is advised when considering St. John's wort, especially if the patient is taking serotonergic medications, due to the risk of serotonin syndrome and potential drug interactions as it is a potent CYP3A4 inducer. It is important to discuss these considerations with the patient and ensure they are aware of the potential risks and benefits.\n",
    "\n",
    "ðŸŸ¦ QUESTION 7: My patient is presenting with a mild severity major depressive episode. All other things being equal and accessible, what does CANMAT recommend for treatment?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient presenting with a mild severity major depressive episode, the CANMAT guidelines recommend that the choice of initial treatment should be made collaboratively between the clinician and the patient. This decision should consider the range of potential treatments, the evidence supporting each, and the patient's personal situation, expectations, and preferences. While the guidelines emphasize the importance of personalized care, they suggest that the severity of depression is a primary factor in treatment selection, along with past treatment responses and availability. Therefore, for mild depression, options such as psychotherapy or lifestyle modifications may be considered, but the final decision should be tailored to the patient's specific needs and preferences.\n",
    "\n",
    "ðŸŸ¦ QUESTION 8: My patient's depression has not responded to the medication dose I started them on a four weeks ago. What should I do next?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "Based on the CANMAT guidelines, the first step when a patient does not respond to an initial antidepressant dose is to optimize the dose. Increasing the dose can be more effective, but it must be balanced against potential side effects and adherence issues (Section: Q.7.c, paragraph id: 198). If optimizing the dose does not lead to improvement, consider switching to another antidepressant or adding an adjunctive medication, especially if there is a partial response and minimal side effects (Section: Q.7.c, paragraph id: 201). Additionally, reassess the diagnosis, comorbidities, and adherence to treatment, and consider laboratory investigations to rule out other contributing factors (Section: Q.7.c, paragraph id: 193).\n",
    "\n",
    "ðŸŸ¦ QUESTION 9: My patient's depression has not responded to the SSRI medication I started them on, even after I optimized and increased the dose up to where they could still tolerate the side effects. I haven't tried anything else yet. What should I do now?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "Based on the CANMAT guidelines, after optimizing the dose of the initial SSRI and ensuring tolerability, the next steps involve either switching to another antidepressant or adding an adjunctive medication. If the patient has shown no response to the initial treatment, switching to another antidepressant may be considered, especially if there are troublesome side effects. However, if there is a partial response and minimal side effects, adding an adjunctive medication might be more appropriate. Additionally, incorporating psychological treatments early in the course is recommended due to their efficacy and low side effect profile.\n",
    "\n",
    "ðŸŸ¦ QUESTION 10: My patient's depression has not responded to the SSRI medication I started them on, even after I optimized and increased the dose up to where they could still tolerate the side effects. They are not interested in psychotherapy. What should I do now?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "In this situation, after optimizing the SSRI dose and considering the patient's lack of interest in psychotherapy, the next step would be to consider switching to another antidepressant or adding an adjunctive medication. The evidence for switching antidepressants is inconsistent, and it is not superior to continuing the same one, especially after the first switch. Therefore, if the patient had a partial response to the initial antidepressant and tolerability is not an issue, adding an adjunctive medication might be a more effective strategy. This approach should be informed by a comprehensive review of previous medication trials and any major side effects experienced.\n",
    "\n",
    "ðŸŸ¦ QUESTION 11: My patient's depression achieved a partial response to the SSRI medication I started them on, but the improvements have been less than hoped. They are not experiencing any side effects from the SSRI. What should I do?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "In this scenario, where there is a partial response to the initial SSRI and no tolerability issues, the CANMAT guidelines suggest considering adjunctive strategies. Adding an adjunctive medication can retain the partial treatment gains from the SSRI and potentially enhance the therapeutic effect by introducing complementary mechanisms of action. This approach is beneficial as it avoids discontinuation symptoms and can target specific residual symptoms. Additionally, Cognitive-behavioral therapy (CBT) is recommended as a second-line adjunctive treatment to further improve outcomes.\n",
    "\n",
    "ðŸŸ¦ QUESTION 12: My patient's severe major depressive episode did not respond to an SSRI, and did not respond to SNRI after switching to it. I tried adding adjunctive pharmacotherapy as well but it did not work. What should I do now?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "Based on the CANMAT guidelines, after unsuccessful trials with an SSRI, SNRI, and adjunctive pharmacotherapy, it is recommended to consider psychological treatments or neuromodulation options. Cognitive-behavioral therapy (CBT) is suggested as a second-line adjunctive treatment for difficult-to-treat depression, as it has shown moderate-quality evidence for improving outcomes when added to usual care. If psychological treatments are not effective or feasible, neuromodulation treatments, which have good evidence for efficacy in treatment-resistant depression, can be considered, although they may be less accessible and involve a higher patient burden.\n",
    "\n",
    "ðŸŸ¦ QUESTION 13: I am about to start my patient on an antidepressant, but I am worried about their likelihood to adhere to medications, and they have abruptly stopped in the past. What medications have the highest risk of antidepressant discontinuation syndrome?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "According to the CANMAT clinical manual, paroxetine and venlafaxine are associated with a high risk of antidepressant discontinuation symptoms. These medications have shorter half-lives, which contribute to a greater incidence and severity of discontinuation symptoms, especially if stopped abruptly. If adherence is a concern, it may be beneficial to consider antidepressants with a lower risk of discontinuation symptoms, such as fluoxetine, which has a long half-life and does not typically require tapering.\n",
    "\n",
    "ðŸŸ¦ QUESTION 14: I am about to start my patient on an antidepressant, but I am worried about their likelihood to adhere to medications, and they have abruptly stopped in the past. What medications available in Canada have the lowest risk of antidepressant discontinuation syndrome?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "According to the CANMAT clinical manual, antidepressants with the lowest risk of discontinuation symptoms include bupropion, fluoxetine, mirtazapine, and vortioxetine. Among these, fluoxetine is particularly noted for not requiring tapering due to its long half-life, which may be beneficial for patients with a history of abruptly stopping medications. These options may be preferable for your patient to minimize the risk of discontinuation syndrome.\n",
    "\n",
    "ðŸŸ¦ QUESTION 15: My patient who I have been treating on antidepressant medication is no longer feeling any of their depressive symptoms. How long should they be on maintenance treatment for?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "According to the CANMAT guidelines, patients who have achieved symptomatic remission should maintain antidepressant treatment for 6 to 12 months after remission to prevent recurrence. This recommendation is based on evidence suggesting that extending maintenance treatment beyond 6 months provides additional benefits compared to stopping earlier. Therefore, it is advisable to continue the medication for at least 6 to 12 months after the patient has become symptom-free.\n",
    "\n",
    "ðŸŸ¦ QUESTION 16: My patient has had recurrent depressive episodes, and has now once again had their symptoms relieved by the medications I've prescribed. They want longer-lasting benefits and want help with preventing recurrent episodes in the future. What should can I offer them?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient with recurrent depressive episodes who seeks long-term benefits and prevention of future episodes, maintenance pharmacotherapy combined with psychotherapy is recommended. Maintenance medication can significantly reduce relapse rates, and flexible dosing is more effective than fixed doses. Additionally, sequential treatment involving psychotherapy, particularly cognitive-behavioral therapy (CBT), can help treat residual symptoms and enhance psychological resilience. This combined approach is especially beneficial for individuals with a high risk of recurrence, and pharmacotherapy should continue alongside psychotherapy to maximize effectiveness (Section: How is Recurrence Prevented?).\n",
    "\n",
    "ðŸŸ¦ QUESTION 17: I am about to start my patient on citalopram. Is there any monitoring or investigations I should order for them based on the guidelines?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "According to the CANMAT guidelines, citalopram carries a risk of QTc prolongation, although the clinical risk is considered low. It has been used safely in large trials of MDD with comorbid cardiovascular disease. While routine laboratory tests are not necessary for monitoring antidepressant treatment, it is important to be aware of this potential risk, especially in patients with pre-existing cardiovascular conditions. Regular monitoring of weight, glucose, and lipid profiles is also recommended if the patient is at risk of weight gain, which can be a side effect of antidepressants.\n",
    "\n",
    "ðŸŸ¦ QUESTION 18: My patient with a moderate severity major depressive episode would like to start a first-line SSRI, but wants to minimize their chances of sexual side effects. What is the best option for them?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient with moderate severity major depressive episode who wishes to start a first-line SSRI while minimizing the risk of sexual side effects, it is important to consider antidepressants that are associated with lower rates of sexual dysfunction. According to the CANMAT guidelines, desvenlafaxine, bupropion, mirtazapine, vilazodone, vortioxetine, and agomelatine are associated with lower rates of sexual side effects. While these are not SSRIs, they may be preferable if minimizing sexual side effects is a priority. Additionally, assessing baseline sexual functioning is important to identify any emergent sexual side effects.\n",
    "\n",
    "ðŸŸ¦ QUESTION 19: My patient with a moderate severity major depressive episode would like to start a first-line SNRI, but wants to minimize their chances of sexual side effects. What is the best option for them?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient with moderate severity major depressive episode who prefers a first-line SNRI and wants to minimize sexual side effects, desvenlafaxine may be a suitable option. According to the CANMAT guidelines, desvenlafaxine is associated with lower rates of sexual side effects compared to other antidepressants with serotonergic effects. It is important to assess the patient's baseline sexual functioning to identify any emergent sexual side effects during treatment.\n",
    "\n",
    "ðŸŸ¦ QUESTION 20: My patient with a moderate severity major depressive episode has tried an SSRI, without good effect, and now wants to try an SNRI. Their top priority is efficacy, and they are not concerned about any specific side effects. What's the best option for them?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "For a patient with a moderate severity major depressive episode who has not responded well to an SSRI and prioritizes efficacy, an SNRI such as duloxetine may be a suitable option. According to the CANMAT guidelines, SNRIs like duloxetine have shown benefits for symptoms such as energy, fatigue, and motivation, which may be advantageous in this context. Additionally, duloxetine is noted for its efficacy in treating comorbid pain conditions, which could be beneficial if the patient experiences such symptoms.\n",
    "\n",
    "ðŸŸ¦ QUESTION 21: When were the latest CANMAT depression guidelines released?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "The latest CANMAT depression guidelines were released in 2023.\n",
    "\n",
    "ðŸŸ¦ QUESTION 22: What type of patient can this app help me treat?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "The app, which integrates the PHQ-9 and GAD-7, can help treat patients with depression and anxiety by allowing them to track their symptoms alongside other health indicators. This tool is particularly useful in measurement-based care, where ongoing monitoring of symptoms is crucial. Additionally, the app's digital format may benefit equity-deserving groups by addressing language, stigma, and geographic disparities, although challenges such as digital literacy and technology costs should be considered.\n",
    "\n",
    "ðŸŸ¦ QUESTION 23: What evidence are the CANMAT depression guidelines based on?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "The CANMAT depression guidelines are based on a systematic literature review focusing on systematic reviews and meta-analyses published since the 2016 guidelines. High-quality, large-sample randomized controlled trials (RCTs) are considered the gold standard for evidence, but due to the volume of available RCTs, the guidelines prioritize systematic reviews and meta-analyses that synthesize many RCTs. Additionally, the guidelines incorporate expert consensus on safety, tolerability, and feasibility to supplement the evidence and ensure a comprehensive and evidence-informed framework for managing major depressive disorder (MDD).\n",
    "\n",
    "ðŸŸ¦ QUESTION 24: What evidence are the recommendation in this app based on?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "The recommendations in the app are based on evidence evaluated through systematic reviews and meta-analyses, as outlined in the CANMAT guidelines. The strength of evidence is assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria, which consider the quality and risk of bias in studies. Additionally, recommendations are supported by expert consensus from the CANMAT editorial group, focusing on factors such as safety, tolerability, and feasibility.\n",
    "\n",
    "ðŸŸ¦ QUESTION 25: What do the levels of evidence correspond to?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "The levels of evidence in the CANMAT guidelines correspond to the strength of the evidence supporting treatment recommendations. Level 1 and Level 2 evidence are required for first-line treatments and indicate higher-quality evidence, often from systematic reviews or large randomized controlled trials. Level 3 evidence supports second-line treatments, while Level 4 evidence is used for third-line treatments. These levels are determined based on the quality and risk of bias in the studies, as well as expert consensus on factors like safety and feasibility.\n",
    "\n",
    "ðŸŸ¦ QUESTION 26: What are risk factors for depression?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "The risk factors for major depressive disorder (MDD) include both static, nonmodifiable factors and dynamic, potentially modifiable factors. Static factors include female sex, family history of mood disorders, history of adverse childhood events or maltreatment, and death of a spouse. Dynamic factors encompass chronic and nonpsychiatric medical illnesses, psychiatric comorbidities (especially anxiety disorders), alcohol and substance use disorders, insomnia, night shift work, periods of hormonal changes, recent stressful life events, job strain, bereavement, peer victimization, gender dysphoria, and a sedentary lifestyle. Understanding these factors can help clinicians address the biological, psychological, and social issues in managing MDD.\n",
    "\n",
    "ðŸŸ¦ QUESTION 27: Should a patient on an antidepressant also see a therapist?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "According to the CANMAT clinical manual, it is recommended for patients who show a poor response to an initial antidepressant to consider adding psychotherapy, specifically Cognitive-behavioral therapy (CBT), as a second-line adjunctive treatment. This approach can help reduce depressive symptoms and increase response and remission rates. Therefore, it is advisable for a patient on an antidepressant to also see a therapist, particularly if they are not experiencing adequate improvement with medication alone. This recommendation aligns with a collaborative treatment plan that incorporates patient preferences and treatment history.\n",
    "\n",
    "ðŸŸ¦ QUESTION 28: I have a patient who often struggles with constipation. Would paroxetine be a good antidepressant to try first?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "Paroxetine may not be the best choice for a patient who struggles with constipation. While the manual does not specifically address constipation, paroxetine is known to have anticholinergic effects, which can exacerbate constipation. Instead, considering antidepressants with a more favorable side effect profile, such as escitalopram or vortioxetine, may be preferable due to their advantages in both efficacy and acceptability (Section: Q.3.e. How is a Pharmacological Treatment Selected?).\n",
    "\n",
    "ðŸŸ¦ QUESTION 29: My patient wants to use an AI app for their depression, is this safe?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "The CANMAT clinical manual indicates that while AI-based chatbots and conversational agents have shown some benefits in trials for depressive and anxiety symptoms, there is currently insufficient evidence to recommend them for the treatment of major depressive disorder (MDD) due to low-quality evidence and potential risks such as inappropriate responses. Therefore, while these tools might offer some support, they should not replace traditional treatments, and their use should be approached with caution. It is advisable to consider other digital health interventions (DHIs) with a stronger evidence base, such as those with positive randomized controlled trials (RCTs) in patients with MDD, and to ensure any app used is evaluated for efficacy, privacy, and security.\n",
    "\n",
    "ðŸŸ¦ QUESTION 30: How do I know if an antidepressant is working?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "The CANMAT guidelines suggest that the effectiveness of an antidepressant is typically assessed by evaluating the balance of efficacy and tolerability. Efficacy is often measured by the response rate, which can be determined through clinical improvement in symptoms of depression. Acceptability, a proxy for tolerability, is assessed by the rate of discontinuation from treatment for any reason. If a patient experiences a significant reduction in depressive symptoms without intolerable side effects, the antidepressant is likely working effectively. Regular follow-up and monitoring are essential to ensure the treatment continues to be beneficial.\n",
    "\n",
    "ðŸŸ¦ QUESTION 31: When a patient is better, how long should they continue their antidepressant for?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "According to the CANMAT guidelines, patients who have achieved symptomatic remission should maintain treatment with antidepressants for 6 to 12 months to prevent recurrence. This recommendation is based on meta-regression evidence indicating that extending maintenance treatment beyond 6 months provides additional benefits compared to stopping earlier. For patients with risk factors for recurrence, longer-term treatment of 2 years or more may be necessary.\n",
    "\n",
    "ðŸŸ¦ QUESTION 32: My patient has not responded to escitalopram at 10 mg, what should I do next?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "In cases where a patient has not responded to an initial antidepressant like escitalopram at 10 mg, the CANMAT guidelines suggest first optimizing the dose. Increasing the dose can be effective, but it must be balanced against potential side effects and adherence issues (Section: Q.7.c. How are Strategies Sequenced When There is a Poor Response to an Initial Antidepressant Treatment?). If dose optimization does not yield results, consider switching to another antidepressant or adding an adjunctive medication. Switching is recommended when there is no response or troublesome side effects, while adjunctive strategies are preferred if there is a partial response with minimal side effects (Section: Q.7.c. How are Strategies Sequenced When There is a Poor Response to an Initial Antidepressant Treatment?).\n",
    "\n",
    "ðŸŸ¦ QUESTION 33: I am considering referring my patient to ECT for their depression. Would I need to stop their medications?\n",
    "\n",
    "ðŸ¤– GPT-4o Answer:\n",
    "According to the CANMAT clinical manual, most antidepressants and other medications can usually be continued during ECT treatment, as concurrent use of antidepressants may improve outcomes. However, certain medications like benzodiazepines and anticonvulsants may interfere with ECT efficacy, and others like lithium and cannabis may worsen cognitive side effects, so these should be discontinued or held before ECT. It is important to evaluate the specific medications your patient is taking and consider these recommendations when planning ECT."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "cl",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
